Roivant Sciences (ROIV) Earnings Call Presentation

Corporate Strategy & Leadership - Eric Venker, MD, was appointed CEO, and Tiago Girao was appointed CFO, signaling a management transition[12] - Immunovant is focused on executing in six announced indications currently underway, including Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE)[12] - The current cash balance provides runway for announced indications into Graves' readout expected in 2027[11] IMVT-1402 Clinical Development & Potential - IMVT-1402 is expected to reach approximately 80% IgG reduction with continued weekly dosing of 600 mg, based on Phase 1 data[20] - A potentially registrational trial for IMVT-1402 in Sjögren's Disease (SjD) is expected to start in Summer 2025[12, 20] - A proof-of-concept study in Cutaneous Lupus Erythematosus (CLE) has been initiated for IMVT-1402, with early positive data[12, 20] - IMVT-1402 has strong patent protection covering composition of matter, method of use, and methods for manufacturing to 2043[20] Market Opportunity & Competitive Landscape - Approved FcRn products generated over $2.4 billion in net sales in their second year post-launch, more than double TNF agents at a similar timepoint[22] - In the US, approximately 90,000 people with Sjögren's Disease with anti-Ro/SSA antibodies represent a target addressable population[26, 38] - In the US, approximately 75,000 people with Cutaneous Lupus Erythematosus uncontrolled on standard of care represent a target addressable population[26, 49] - Up to 50% of SCLE/CCLE patients failing standard of care, represent an untapped market opportunity[54]